In a man not taking exogenous testosterone who has elevated sex hormone‑binding globulin, what are the likely causes and how should low free testosterone be evaluated and managed?

Elevated SHBG with Low Free Testosterone in Men Not Taking Exogenous Testosterone

Understanding the Hormonal Pattern

When a man not using testosterone has elevated sex hormone-binding globulin (SHBG), the most common causes are aging, hyperthyroidism, hepatic disease, HIV/AIDS, smoking, or certain medications (anticonvulsants, estrogens, thyroid hormone). 1 This elevated SHBG binds circulating testosterone, creating a discrepancy where total testosterone may appear normal or borderline-low while free (bioavailable) testosterone is frankly low—a condition termed "functional hypogonadism." 2

Key Physiologic Principle

• SHBG acts as a gatekeeper for testosterone action: elevated SHBG sequesters testosterone in the circulation, reducing the free fraction available to tissues despite potentially normal total testosterone levels 3
• Importantly, in vivo studies show that elevated SHBG does not necessarily lower non-SHBG-bound testosterone when the hypothalamic-pituitary-gonadal axis is intact, because the body compensates by increasing total testosterone production 4
• However, when this compensatory mechanism fails or is overwhelmed, true biochemical hypogonadism results 2

---

Diagnostic Evaluation Algorithm

Step 1: Confirm True Hypogonadism

Obtain two separate fasting morning total testosterone measurements (8–10 AM) to establish whether total testosterone is < 300 ng/dL. 1, 2 Single measurements are insufficient due to diurnal variation and assay variability. 2

• If both values are < 300 ng/dL: proceed to Step 2 2
• If values are 231–346 ng/dL (gray zone): measure free testosterone by equilibrium dialysis or calculate free androgen index (FAI) 2
• If total testosterone is > 350 ng/dL: testosterone therapy is not indicated regardless of symptoms 2

Step 2: Measure Free Testosterone Accurately

Free testosterone by equilibrium dialysis is the gold standard; when unavailable, calculate the free androgen index (FAI) as (total testosterone ÷ SHBG) × 100. 2 Direct immunoassays for free testosterone are inaccurate and should be avoided. 3

• FAI < 30 indicates true hypogonadism even when total testosterone is borderline-normal 2
• In men with markedly elevated SHBG and diminished libido, the pre-test probability of biochemical hypogonadism is high 2

Step 3: Distinguish Primary from Secondary Hypogonadism

Measure serum LH and FSH after confirming low testosterone to differentiate testicular failure (primary) from hypothalamic-pituitary dysfunction (secondary). 1, 2, 5

• Low or inappropriately normal LH/FSH with low testosterone = secondary hypogonadism 1, 5
• Elevated LH/FSH with low testosterone = primary hypogonadism 1
• This distinction is critical: secondary hypogonadism patients can potentially restore both testosterone and fertility with gonadotropin therapy, whereas primary hypogonadism patients require testosterone replacement (which permanently suppresses fertility) 1, 2

Step 4: Identify Reversible Causes of Elevated SHBG

Screen for conditions that elevate SHBG and address them before considering testosterone therapy:

• Hyperthyroidism: measure TSH 1, 2
• Hepatic disease (cirrhosis): obtain liver function tests and hepatitis serologies 1, 2
• HIV/AIDS: test if risk factors present 1
• Medications: review anticonvulsants, estrogens, thyroid hormone 1
• Smoking: counsel cessation 1

Step 5: Evaluate for Secondary Causes of Hypogonadism

If secondary hypogonadism is confirmed (low LH/FSH), systematically exclude reversible etiologies:

• Hyperprolactinemia: measure serum prolactin; if > 1.5× upper limit of normal, order pituitary MRI 2
• Obesity-associated hypogonadism: calculate BMI and waist circumference; excess adipose tissue increases aromatization of testosterone to estradiol, causing estradiol-mediated negative feedback on LH secretion 1, 2
• Metabolic syndrome/type 2 diabetes: obtain fasting glucose, HbA1c, lipid profile 1, 2
• Chronic systemic illness: screen for HIV, chronic kidney disease, chronic liver disease, inflammatory conditions 2
• Hemochromatosis: measure iron saturation and ferritin 2
• Pituitary lesions: if testosterone < 150 ng/dL with LH/FSH < 1.5 IU/L, or if visual field defects or anosmia present, order pituitary MRI immediately 2

---

Management Strategy

First-Line: Address Underlying Causes

Before initiating testosterone therapy, treat reversible conditions:

• Obesity-associated secondary hypogonadism: implement hypocaloric diet (500–750 kcal/day deficit) and structured exercise (≥ 150 min/week moderate-intensity aerobic activity plus resistance training 2–3×/week) 2
  • Weight loss of 5–10% can significantly increase endogenous testosterone production 2
• Hyperthyroidism: treat with antithyroid medications, radioiodine, or surgery 1
• Hepatic disease: optimize liver function; in cirrhosis, use free testosterone index (total testosterone/SHBG ratio < 0.3) to define hypogonadism 2
• Medication adjustment: discontinue or substitute SHBG-elevating drugs when feasible 1

Second-Line: Pharmacologic Therapy

For Men Desiring Fertility Preservation

Gonadotropin therapy (recombinant hCG plus FSH) is mandatory for secondary hypogonadism with fertility concerns; testosterone replacement is absolutely contraindicated because it causes prolonged, potentially irreversible azoospermia. 1, 2

• hCG stimulates testicular Leydig cells to produce testosterone 2
• FSH stimulates Sertoli cells to support spermatogenesis 2
• Combined therapy restores both testosterone levels and sperm production 1, 2

Alternative: Selective Estrogen Receptor Modulators (Off-Label)

Clomiphene citrate 25–50 mg three times weekly can stimulate endogenous testosterone production in secondary hypogonadism by blocking estradiol-mediated negative feedback. 2

• Indicated when LH/FSH are low or low-normal with low testosterone 2
• Preserves fertility by maintaining endogenous gonadotropin secretion 2
• Monitor testosterone, estradiol, LH, FSH at 6 weeks; target mid-normal testosterone (500–600 ng/dL) 2

For Men Not Seeking Fertility

If lifestyle modification fails and fertility is not desired, initiate testosterone replacement therapy only after confirming both biochemical hypogonadism (two morning testosterone < 300 ng/dL) and specific symptoms (diminished libido, erectile dysfunction). 1, 2

• Transdermal testosterone gel 1.62% at 40.5 mg daily is first-line due to stable day-to-day levels and lower erythrocytosis risk compared to injectables 1, 2
• Intramuscular testosterone cypionate/enanthate 100–200 mg every 2 weeks is a more economical alternative but carries higher erythrocytosis risk (44% vs. 15% with transdermal) 2
• Target mid-normal testosterone levels (450–600 ng/dL) 2

---

Expected Treatment Outcomes

Testosterone therapy produces small but significant improvements in sexual function and libido (standardized mean difference 0.35), with little to no effect on physical functioning, energy, vitality, depressive symptoms, or cognition. 1, 2

• Primary indication is sexual dysfunction (diminished libido, erectile dysfunction) 1, 2
• Fatigue, low energy, mood disturbances, and cognitive complaints show minimal or no improvement even with confirmed hypogonadism 2
• Modest improvements in metabolic parameters (insulin resistance, triglycerides, HDL cholesterol) may occur 2

---

Monitoring Requirements

Pre-Treatment Baseline

• Hematocrit/hemoglobin: document baseline; hematocrit > 54% is an absolute contraindication 2
• PSA (men > 40 years): PSA > 4.0 ng/mL requires urologic evaluation and negative prostate biopsy before therapy 2
• Digital rectal examination: assess for palpable prostate nodules 2
• Fasting glucose and HbA1c: exclude diabetes 2
• Lipid profile: baseline metabolic assessment 2

During Treatment

• 2–3 months after initiation: measure testosterone (midway between injections for injectables), hematocrit, PSA 2
• Every 3–6 months during first year: repeat testosterone, hematocrit, PSA, lipid profile, digital rectal exam 2
• Annually once stable: testosterone, hematocrit, PSA, lipid profile, digital rectal exam 2

Safety Thresholds

• Withhold testosterone if hematocrit > 54%; consider phlebotomy in high-risk cases 1, 2
• Urologic referral if PSA increases > 1.0 ng/mL in first 6 months or > 0.4 ng/mL/year thereafter 2
• Discontinue at 12 months if no improvement in sexual function to avoid unnecessary long-term exposure 2

---

Critical Pitfalls to Avoid

• Never diagnose hypogonadism on a single testosterone measurement or symptoms alone; require two morning values < 300 ng/dL plus specific symptoms 1, 2
• Never omit LH/FSH testing after confirming low testosterone; the distinction between primary and secondary hypogonadism directs therapy and fertility counseling 1, 2, 5
• Never start testosterone without confirming the patient does not desire fertility; exogenous testosterone causes prolonged azoospermia 1, 2
• Never use direct immunoassays for free testosterone in men with abnormal SHBG; use equilibrium dialysis or calculate FAI 2, 3
• Never initiate testosterone for weight loss, energy improvement, or athletic performance; these are not evidence-based indications 1, 2
• Never assume age-related decline in young men; systematically investigate for secondary causes of hypogonadism 2
• Approximately 25–30% of men receiving testosterone do not meet diagnostic criteria for hypogonadism, and 50% never have their levels rechecked—strict adherence to diagnostic and monitoring protocols is essential 2